(NASDAQ: CCCC) C4 Therapeutics's forecast annual revenue growth rate of -9.13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.4%.
C4 Therapeutics's revenue in 2026 is $35,039,000.On average, 9 Wall Street analysts forecast CCCC's revenue for 2026 to be $3,325,246,401, with the lowest CCCC revenue forecast at $1,567,340,233, and the highest CCCC revenue forecast at $5,527,888,436. On average, 9 Wall Street analysts forecast CCCC's revenue for 2027 to be $2,898,718,254, with the lowest CCCC revenue forecast at $1,567,340,233, and the highest CCCC revenue forecast at $4,004,468,177.
In 2028, CCCC is forecast to generate $3,405,704,840 in revenue, with the lowest revenue forecast at $1,567,340,233 and the highest revenue forecast at $4,262,820,962.